- Trials with a EudraCT protocol (7)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
7 result(s) found for: Life-years lost.
Displaying page 1 of 1.
EudraCT Number: 2018-003662-14 | Sponsor Protocol Number: GN17CA082 | Start Date*: 2019-05-13 | |||||||||||
Sponsor Name:NHS Greater Glasgow and Clyde [...] | |||||||||||||
Full Title: Patiromer-facilitated, dose-escalation of mineralocorticoid antagonists for the management of worsening congestion in people with heart failure and hyperkalaemia. A Phase IV, registry-based, rand... | |||||||||||||
Medical condition: People with heart failure, worsening symptoms and signs of congestion and serum potassium >5mmol/L | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-004012-10 | Sponsor Protocol Number: MODIFI | Start Date*: 2021-06-17 |
Sponsor Name:UZ Leuven | ||
Full Title: Model-informed infliximab dose de-escalation following earlier dose escalation in adult patients with inflammatory bowel diseases | ||
Medical condition: Inflammatory bowel diseases - Crohn's disease - ulcerative colitis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2010-023649-31 | Sponsor Protocol Number: HT-ANAM-302 | Start Date*: 2011-07-29 | ||||||||||||||||
Sponsor Name:Helsinn Therapeutics (U.S.), Inc. | ||||||||||||||||||
Full Title: Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer – Cachexia (NSCLC-C): A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study to Evaluate the Safety and Efficacy ... | ||||||||||||||||||
Medical condition: Non-Small Cell Lung Cancer related Cachexia (NSCLC-C) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: HU (Completed) GB (Completed) PL (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2019-003913-32 | Sponsor Protocol Number: HeLeNe-18-02 | Start Date*: 2020-11-18 |
Sponsor Name:Ruprecht-Karls-University of Heidelberg Medical Faculty represented in law by Heidelberg University Hospital | ||
Full Title: Randomized phase-III study to compare two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and to compare intensive postremission therapy double blinded with or without ... | ||
Medical condition: acute myeloid leukemia (AML) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-000364-15 | Sponsor Protocol Number: SUNRISE-CRC | Start Date*: 2019-09-11 |
Sponsor Name:VU University Medical Center, Department of Medical | ||
Full Title: A randomized phase II/III study of pulsatile high-dose sunitinib versus TAS-102 in patients with metastatic colorectal carcinoma (mCRC). | ||
Medical condition: Advanced colorectal tumors | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2017-005120-16 | Sponsor Protocol Number: 62638 | Start Date*: 2018-11-02 | |||||||||||
Sponsor Name:Amsterdam UMC, Location VUmc | |||||||||||||
Full Title: Ulipristal versus standard surgical treatment in symptomatic uterine fibroids | |||||||||||||
Medical condition: Uterine fibroids are very common during reproductive years in women. Minimally invasive treatments are emerging. Myomectomy is the gold standard, preferably laparoscpically, because it removes the ... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: NL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-023650-36 | Sponsor Protocol Number: HT-ANAM-303 | Start Date*: Information not available in EudraCT |
Sponsor Name:Helsinn Therapeutics (U.S.), Inc. | ||
Full Title: Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer – Cachexia (NSCLC-C): An Extension Study (ROMANA-3) | ||
Medical condition: Non-Small Cell Lung Cancer related Cachexia (NSCLC-C) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: HU (Completed) BE (Completed) NL (Completed) GB (Completed) ES (Completed) CZ (Completed) PL (Completed) DE (Completed) IT (Completed) SI (Completed) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
